You are here


Founding Member

Reshema Kemps-Polanco, MBA

Executive Vice President and U.S. Head, Novartis Oncology

Reshema Kemps-Polanco is Executive Vice President and US Head, Novartis Oncology, responsible for the commercialization of innovative cancer medicines, including complex platforms such as cell and gene therapy, and radiopharmaceuticals. With over 20 years of U.S. and global healthcare experience, she is pursuing a transformational growth strategy to sustain a leading position in the world’s largest healthcare market across oncology and hematologic diseases.

Reshema returned to Novartis in 2021 after spending seven years at Johnson and Johnson, where she served as President of Janssen’s Cardiovascular and Metabolism Unit in the U.S. and concurrently as President, Janssen Pharmaceuticals, Puerto Rico. Prior positions at Janssen include serving as Vice President across multiple roles in the U.S., as well as the Global Oncology organization. Before joining Johnson and Johnson, Reshema spent 15 years at Novartis where she led multiple commercial teams across oncology and specialty business units.

Reshema is a board member of the Healthcare Leadership Council, a coalition of chief executives focused on policies that make quality healthcare accessible to all Americans.

Reshema earned an M.B.A from Rutgers University, and M.A. in Industrial/Organizational Development from Louisiana Tech University and a B.A. from the University of Louisiana at Monroe.

CEO Cancer Gold Standard™

Gold Standard  Employer

Gold Standard Employer Since 2006 | Global Gold Standard Employer Since 2013


At Novartis Oncology, our mission is to discover new ways to improve and extend the lives of people with cancer. This starts with the health of our associates. Our accreditation with the CEO Cancer Gold Standard has provided us for the past 10 years with a valuable framework from which to structure our programs geared toward preventing cancer, providing support during the cancer journey, and encouraging the overall health and well-being of our associates.

— Reshema Kemps-Polanco, MBA

Gold Standard  Task Force Participation

Gold Standard Co-Chair, Accreditation Review Board Member & Member: Roy D. Baynes, MD, PhD, Senior Vice President & Head of Global Clinical Development, Chief Medical Officer

Global Gold Standard  Task Force Participation

Global Gold Standard Subcommittee Member: Dawn Aubel, EdD, MS, MPH, APNc, Medical Science Liaison Hematology

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Elizabeth Barrett, Chief Executive Officer, Novartis Oncology; Maya R. Said, Global Head, Oncology Policy and Market Access


Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit